282 related articles for article (PubMed ID: 18280742)
1. 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: a strategic design in anti-urease agents.
Zaheer-ul-Haq ; Lodhi MA; Ahmad Nawaz S; Iqbal S; Mohammed Khan K; Rode BM; Atta-ur-Rahman ; Choudhary MI
Bioorg Med Chem; 2008 Mar; 16(6):3456-61. PubMed ID: 18280742
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
3. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
4. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
5. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
6. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
8. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.
Liao SY; Qian L; Miao TF; Lu HL; Zheng KC
Eur J Med Chem; 2009 Jul; 44(7):2822-7. PubMed ID: 19167135
[TBL] [Abstract][Full Text] [Related]
9. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
10. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure-activity relationship study for phenylsulfonyl carboxylates using CoMFA and CoMSIA.
Liu X; Yang Z; Wang L
Chemosphere; 2003 Dec; 53(8):945-52. PubMed ID: 14505717
[TBL] [Abstract][Full Text] [Related]
12. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
13. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
14. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
16. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
19. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion.
Elnagar AY; Wali VB; Sylvester PW; El Sayed KA
Bioorg Med Chem; 2010 Jan; 18(2):755-68. PubMed ID: 20022507
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K.
Pan X; Tan N; Zeng G; Han H; Huang H
Bioorg Med Chem; 2006 Apr; 14(8):2771-8. PubMed ID: 16377193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
